Mark Hall MD in Bend, Oregon

Home Oregon Bend

Mark Hall MD has Dermatology as his primary medical specialty. Their primary office is: 388 Sw Bluff Dr in Bend, Oregon.

They're a part of the: Central Oregon Dermatology, Pc medical group which has around 2 members. You can call their office at 541-678-0020 to schedule an appointment. They also accept the Medicare-approved amount as payment in full. They attended Georgetown University School Of Medicine and graduated in 1998 (around 27 years of experience). They are not listed as doing telehealth appointments, but this may have changed. It can't hurt to call and check. If anything it may encourage them to make them available if they are not currently.

Mark A Hall MD Office Phone and Directions

Mark Hall MD
Central Oregon Dermatology, Pc
388 Sw Bluff Dr
Bend, Oregon 97702
541-678-0020

Patient Ratings
Please rate your experience with Mark Hall MD below to help others make a more informed decision. Thanks!

Current Rating: Loading...

Phone: 541-678-0020

Enter a starting address:

Healthcare Info for Mark Hall MD

Medical School: Georgetown University School Of Medicine
Graduation Year: 1998
The Primary Medical Specialty for Mark Hall MD is listed as: Dermatology
Credentials: MD
Additional Credentials:
Approximate Years of Experience: 27
PAC (PECOS ID)#: 4587667134
NPI #: 1609815166
NPI Created On: 06/06/2006
NPI Last Updated Listed as: 02/21/2013
Primary Taxonomy Code: 207N00000X
License Number:
MD26648
Listed Gender: Male

Insurance, Services, Charges

Forms of insurance accepted by include, but are not limited to:

Humana
Moda Health Plan, Inc.
PacificSource Health Plans
Providence Health Plan
Medicare

They are listed as accepting new patients.

Languages spoken by staff include: English.

Services and Procedures include:

Tangential biopsy of single skin lesion
Tangential biopsy of additional skin lesion
Removal of malignant growth (1.1 to 2.0 centimeters) of the trunk, arms, or legs
Removal of malignant growth (2.1 to 3.0 centimeters) of the trunk, arms, or legs
Repair of wound (2.6 to 7.5 centimeters) of the scalp, underarms, trunk, arms, and/or legs
Destruction of skin growth
Destruction of 2-14 skin growths
Destruction of 15 or more skin growths
Destruction of up to 14 skin growths
Destruction of malignant growth (0.6 to 1.0 centimeters) of trunk, arms, or legs
Destruction of malignant growth (1.1 to 2.0 centimeters) of trunk, arms, or legs
Destruction of malignant growth (1.1 to 2.0 centimeters) of scalp, neck, hands, feet, or genitals
Destruction of malignant growth (1.1 to 2.0 centimeters) of face, ears, eyelids, nose, lips, or mouth
Pathology examination of tissue using a microscope, intermediate complexity
Application of light and light-sensitive drugs following removal of premalignant thickened skin growth, per day
New patient office or other outpatient visit, typically 20 minutes
New patient office or other outpatient visit, typically 30 minutes
Established patient office or other outpatient visit, typically 10 minutes
Established patient office or other outpatient visit, typically 15 minutes
Established patient office or other outpatient, visit typically 25 minutes

They took part in Medicare's Electronic Health Record Incentive Program which was designed to help move people over to electronic records and improve the systems that were already in place.
They took part in the Medicare Physician Quality Reporting System (PQRS).

Open Payments Data. This can include items to test (Durable Medical Equipment (DME)), Biological, Drug Samples, etc. This data must be reported to CMS.

Payments Total: $20

Number of Payments:: 1

Form of Payment: In-kind items and services

Third party is a Charity:: No

Record ID:: 788475013

Being Disputed:: No

Product Related: Yes

Drug or Biological: Biological

Product Category #1: Immunology

Name of Drug #1: REMICADE

Open Associated Drug #1: 57894-030-01

Drug or Biological: Biological